Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma
- 1 October 2017
- journal article
- research article
- Published by Elsevier in Human Pathology
- Vol. 68, 103-111
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Health and Welfare (HI15C0789)
- National Research Foundation of Korea
- Ministry of Education, Science and Technology (NRF-2016R1D1A1B01014311)
This publication has 23 references indexed in Scilit:
- Counter-regulation of rejection activity against human liver grafts by donor PD-L1 and recipient PD-1 interactionJournal of Hepatology, 2016
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialThe Lancet, 2016
- FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1The Oncologist, 2016
- Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patientsVirchows Archiv, 2016
- Pembrolizumab for the Treatment of Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Immune Checkpoint Modulation for Non–Small Cell Lung CancerClinical Cancer Research, 2015
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cellsJournal of Experimental Medicine, 2009
- Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasionCancer Immunology, Immunotherapy, 2006
- Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasionNature Medicine, 2002